58
Participants
Start Date
December 22, 2022
Primary Completion Date
October 30, 2025
Study Completion Date
June 30, 2026
ONC-392
ONC-392 will be given by IV infusion, q3w.
Pembrolizumab
Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.
Women's Cancer Care Associates, LLC. 405, Albany
Baptist MD Anderson Cancer Center, 404, Jacksonville
Norton Cancer Institute - St. Matthews, 416, Louisville
Baptist Health Lexington, 407, Lexington
The Ohio State University James Cancer Center, 412, Columbus
Northwest Cancer Centers - Dyer, IN - USOR, 422, Dyer
Medical College of Wisconsin, 408, Milwaukee
Minnesota Oncology Hematology, P. A. - USOR, 421, Maplewood
Cancer Treatment Centers of America, Chicago. 410, Zion
Sudarshan Sharma, MD. LTD. 414, Hinsdale
Willis-Knighton Physician Network / Gynecologic Oncology Associates, 409, Shreveport
Texas Oncology - Northeast Texas - USOR, 423, Tyler
Texas Oncology, P.A., Fort Worth - USOR. 420, Fort Worth
Texas Oncology, P. A. Woodlands - USOR, 418, The Woodlands
Texas Oncology, P. A. - Austin, USOR. 417, Austin
Honor Health, USOR, 406, Phoenix
Cancer Treatment Centers of America, Phoenix. 403, Goodyear
Center of Hope, 413, Reno
Oncology Associates of Oregon, P. C. - USOR. 419, Eugene
Nuvance Health System, 401, Danbury
The Valley Hosptial, Inc. 411, Ridgewood
Merck Sharp & Dohme LLC
INDUSTRY
GOG Foundation
NETWORK
OncoC4, Inc.
INDUSTRY